Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Our People
aida_habtezion_v2_790x500_0.png
Aida Mobile Tile

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Changing careers in the middle of a pandemic is no small endeavor. But when Aida Habtezion, M.D., learned about the opportunity to serve as Pfizer’s new Chief Medical Officer, she couldn’t pass it up.

Learn More

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500.png
young_woman_getting_vaccinated_1000x450.png

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

More Here

Global Survey Results: Cancer & Aging

News
World_Cancer_Day_790X500_0.jpg
World_Cancer_Day_1000X450_0.jpg

Global Survey Results: Cancer & Aging

This World Cancer Day, we surveyed older people living with cancer and their caregivers.

Learn about the findings

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

One Year Later: What We Have Learned

Your Health
one_year_later_image_380x700.png
one_year_later_image_1000x450.jpg

One Year Later: What We Have Learned

Thoughts from our Chairman and CEO on a year defined by loss, learning and an approaching liberation.

Read More

VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500.png
GettyImages-1208505315_1000x450_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Latest News

Pfizer Initiates Phase 1 Study of Novel Oral…

In-vitro studies conducted to date show that the clinical candidate PF-07321332 is a potent protease inhibitor with potent anti-viral activity against SARS-CoV-2 This is the first orally administered coronavirus-specific investigational protease inhibitor to be evaluated in clinical studies, and follows Pfizer’s intravenously administered investigational protease inhibitor, which is currently being evaluated in a Phase 1b multi-dose study in hospitalized clinical trial participants with COVID-…
Read more